SPOTLIGHT -
Treatment with Teclistamab Following Progression on CAR-T in R/R MM
The panel shares their experiences with the sequencing of BCMA-targeting therapies in MM, with particular focus on treatment of patients who progress on CAR T-cell therapy with teclistamab.
Bispecific Antibodies in Development for the Treatment of R/R MM
Dr Jack Khouri highlights recent data updates on other BCMA-targeting bispecific antibodies that are in clinical development in multiple myeloma.
Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM
Maria-Victoria Mateos, MD, PhD, reviews how she manages the side effects of teclistamab, including cytokine release syndrome, in patients with relapsed/refractory multiple myeloma.
Mechanism of Action of Teclistamab in R/R MM and Data Updates
Melissa Alsina, MD, explains the mechanism of action, data updates and dosing schedule of the BCMA-targeting bispecific antibody teclistamab.
Selecting Patients with MM for Teclistamab and Optimal Sequencing
The panel discusses their potential treatment approaches for the presented patient case and how they select patients with relapsed/refractory MM for teclistamab and optimally sequence therapies.
Patient Case 1: A 68-Year-Old with R/R MM Treated with Teclistamab
Jack Khouri, MD, presents the case of a 68-year-old patient with relapsed/refractory multiple myeloma and extramedullary disease treated with teclistamab.
Clinical Practice Perspectives on Treatment of MM with Bispecifics
Before closing out their discussion on multiple myeloma management, panelists reflect on real-world clinical practice perspectives on treatment with bispecifics.
Selecting and Sequencing Bispecifics and CAR-T Therapies in R/R MM
A review of novel treatment modalities for relapsed/refractory multiple myeloma, with a focus on selecting and sequencing bispecific antibodies and CAR T-cell therapies.
Patient Case 3: Relapsed/Refractory Multiple Myeloma
Expert panelists center discussion on a final patient case to review the identification and management of relapsed/refractory multiple myeloma.
Treatment Strategies for Patients With Transplant-Ineligible NDMM
Expert perspectives on selection of induction therapy for patients with transplant-ineligible newly diagnosed multiple myeloma.
Patient Case 2: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Panelists move on to review a patient case of transplant-ineligible newly diagnosed multiple myeloma and highlight clinical workup strategies.
Optimal Selection of Therapy for Patients With Transplant-Eligible NDMM
A focused discussion on navigating the treatment armamentarium for patients with transplant-eligible newly diagnosed multiple myeloma.
Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma
Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists consider optimal workup and management strategies.
